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ABSTRACT 
Background: Uncontrolled asthma symptoms will exacerbate asthma. Aminofilin is now rarely used as asthma medication 
abroad because it shows major side effects, unlike in Indonesia, which is still widely used with relatively rare side effects 
events. Aminophylline have relatively more affordable price compared to salbutamol, the first-line option in the 
management of asthma exacerbations requirements. Both of these drugs have a risk of causing electrolyte disturbances, 
which could endanger the patients. Considering the individual drug side effects, so it important to study the safety of the 
medicine to ascertain whether there are differences in the incidence of electrolyte disturbances by both drugs. 
Objective: The main objective of this study was to determine differences in the incidence of electrolyte disturbances in 
patients with asthma exacerbations prescribed with aminophylline and salbutamol at a hospital in Surabaya. 
Method: This study design is a cross-sectional study of inpatient adult asthma exacerbations in emergency room (ER), 
using two groups, namely the group receiving intravenous aminophylline therapy (n = 22), and the group receiving 
nebulized salbutamol therapy (n = 21). 
Result: There is no significant difference between in intravenous aminophylline anda nebulized salbutamol group. And 
there is no significant difference in sodium (p>0,866) and potassium (p>0,470) level in blood as a respon to the asthma 
exacerbations treatment by intravenous aminophylline compared  to nebulized salbutamol. 
Conclusion: Although there was no significant difference in the incidence of electrolyte disturbances in both drugs, but 
close monitoring is still needed to prevent any side effects incident. 
 
Keywords: asthma exacerbations, electrolyte disturbance, aminofilin, salbutamol 
 
INTRODUCTION 
Asthma is a heterogeneous disease which can be caused by 
a variety of etiologies. These disease is one of the major 
health problems in the world1. Although new drugs and 
evidence-based guidelines have been developed in recent 
years however no major changes in the morbidity and 
mortality of asthma2. The incidence of worsening asthma 
symptoms can cause serious problems to the incidence of 
asthma exacerbations that can ended into death. 
Salbutamol is a bronchodilator which belonged to the 
short-acting beta-2 agonist (SABA), the first line option in 
the management of asthma exacerbations1,3. Contrast to 
methylxanthines (aminophylline and theophylline), 
salbutamol has higher efficiency than methylxanthines. 
Methylxanthine is used as an adjunctive therapy in the 
management of asthma if therapeutic effectiveness is not 
optimal, as well as its role in the management of asthma 
exacerbations is still controversial1. Theophylline belong 
to methylxanthines, but its use in asthma has been reduced 
due to the high frequency of side effects and relatively low 
effectiveness and slower1,4. Aminophylline is a derivative 
of theophylline with addition of ethylenediamine from  a 
water soluble salt complex. Aslaksen et al.(1981)5 prove 
that aminophylline at a comparable concentration with 
intravenous and oral theophylline did not differ 
significantly in farmakokinetiknya or binding proteins in 
the blood, so it can be considered the same. Theophylline/ 
aminophylline has a narrow therapeutic range and narrow  
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variations in hepatic metabolism and clearance so that 
might have risks of causing ADR (adverse drug 
reactions)6. Many evidences regarding the events of 
theophylline and aminophylline ADR have many 
uncovered yet7-11. so its use was abandoned in a foreign 
country, but in Indonesia, theophylline is still be used in 
the treatment of asthma exacerbations. In Indonesia, 
aminophylline/ theophylline is one of the asthma drug that 
is often used in the treatment of asthma exacerbations in 
the hospital. Aminophylline even is included in the list of 
DOEN (Daftar Obat Essensial Nasional) 2013. In East 
Java, aminophylline and theophylline in the treatment of 
acute asthma is still widely used in the treatment of asthma 
exacerbations main hospital12-14. The effect of a drug ADR 
can be individualized, including the effects of treatment 
with theophylline during treatment of asthma. 
Interindividual variability in the distribution and 
elimination kinetics of theophylline will result in 
differences in levels of theophylline in plasma, leading to 
clinical consequences which can not be predicted. The 
differences in therapeutic response in inidividual 
theophylline, can be either the dose or doses toxic 
subterapetik15. Genetic factors are among the factors that 
cause a different response to asthma therapy16.  The use of 
beta-agonists and methylzanthine can increase the risk of 
an occurrence of hyponatremia hypokalemia. As has been 
observed by Mohammad et al. (2014)17. which examines 
electrolyte disturbance in chronic asthma (outpatient) and 
exacerbation of asthma. The results showed that incidence 
of hyponatremia is low (4%) in stable asthmatic patients 
dan no abnormalities were noted in serum sodium level the 
exacerbation of asthma. In contrast to the results in the 
levels of potassium, more patients with acute asthma 
exacerbation (54%) had hypokalemia and, there was a 
significant decrease in potassium level in these patients 
than those with stable bronchial asthma. Hypokalemia is a 
side effect that often occurs in both beta-2 agonist 
(salbutamol)1 and methylxanthine (aminophylline). 
Information about the side effects from these drugs was 
limited and outdated as has been done by Whyte et 
al.(1988)18 Hung et al., (1999)19 Hung et al. (1999) 
suspected the existence of a mechanism similar to the 
effects of beta-2 agonist bronchodilation with the 
incidence of hypokalemia. It mentioned that salbutamol 
inhalation significantly improved asthmatic symptoms as 
demonstrated by increasing of expiratory flow and venous 
oxygen tension, and decreasing of respiratory rate, clinical 
scores, and venous PCO2 tensions19. Although the 
incidence of hypokalemia tend to be more frequent, but 
they still need to be a concern in the treatment of asthma 
exacerbations. Therefore, it is necessary to study in this 
effect to patients Indonesia in order to determine 
differences in the incidence of electrolyte disturbances in 
patients with asthma exacerbations medicated with 
aminophylline and salbutamol at a hospital in Surabaya. 
 
METHOD 
This study design is cross-sectional study of inpatient in 
emergency room (ER). The variables of this study 
consisted of the independent variable, which were 
treatments exacerbations of asthma (aminophylline 
intravenous and nebulized salbutamol), and dependent 
variables which were sodium and potassium levels in the 
blood. Data were collected from January 2014 to June 
2015 in some hospitals in Surabaya, Indonesia. 
Population and Sample Research. The population were all 
patients with exacerbations of asthma in some ER in 
hospital in Surabaya. The study sample were all patients 
with exacerbation asthma in hospital in Surabaya who 
fulfill the inclusion and exclusion criteria of the study. 
Inclusion criteria for the study sample were: (1) aged 
adults (18 years)20 ; and (2) willing to be the subject of 
research. Exclusion criteria for the study sample were: (1) 
Patient-lactating pregnant or taking oral contraceptives;21 
(2) Patients with impaired renal function or hepatic 
impairment; (3) The patient smoked or quit smoking <2 
years, coffee consumption; (4) The patient had respiratory 
problems besides asthma that can affect clinical outcomes 
of the treatment. 
Method Of Collecting Data. Ethics test has been carried 
out in each of several hospitals in Surabaya according to 
existing procedures. Then the data collection is done with 
stand-by in the ER. Currently no exacerbation of asthma 
patients who meet the criteria, then the patient was asked 
to fill his willingness and informed consent. The patient's 
body temperature measurements were taken immediately  
Table 1: Characteristics of Research Subjects in Related to Sex, Age, and Medical History 
Characteristics Details intravenous aminophylline (n:22) nebulized salbutamol  
(n:21) 
Sex: Male 5 10 
Female 11 11 
Age (years): 17-25 3 5 
26-35 3 3 
36-45 4 3 
46-55 5 4 
56-65 1 5 
>65 0 1 
average: 39.25 42.38 
Medical history: asthma 15 18 
asthma + gastritis  1 
asthma + type 2 diabetes mellitus  1 
asthma + dyslipidemia 1 1 
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(to ensure the presence of infection), then performed blood 
sampling before getting treatment for an unknown levels 
of electrolyte (sodium and potassium). Samples were 
treated for 1 hour (aminophylline intravenous or nebulized  
salbutamol), then blood drawn back (t1). Results of 
laboratory examination on t0 and t1 then compared to 
observe changes in the use of electrolyte nebulized 
salbutamol in patients with asthma exacerbations in 
Surabaya. The patient's body temperature measurements 
were taken immediately (to ensure the presence of 
infection), then performed blood sampling before getting 
treatment for an unknown levels of electrolyte (sodium and 
potassium). Samples were treated for 1 hour 
(aminophylline intravenous or nebulized salbutamol), then 
blood drawn back (t1). Results of laboratory examination 
on t0 and t1 then compared to observe changes in the use of 
aminophylline intravenous electrolytes with nebulized 
salbutamol in patients with asthma exacerbations in 
Surabaya. The research sample was also interviewed about 
the clinical symptoms of hyponatremia and hypokalemia 
to determine differences in clinical symptoms. Conducted 
interviews to patients about medicines that are used before 
MRS (hospital admission) to determine whether the 
previous drug can affect the results or not. There are events  
Table 2: Frequency Distribution of Sodium Levels Before and After Administration of Exacerbation Treatment with 
Aminofilin Intravenous or Nebulized Salbutamol 
Intervention Group Intravenous Aminophylline  
(n:22) 
Nebulized Salbutamol  
(n:21) 
Total 
Initial conditions before being given treatment (t0) 
Hyponatremia (% of subjects) 0 (0.00%) 1 (2.32%) 1 (2.32%) 
Normal  (% of subjects) 22 (51.17%) 19 (44.19%) 41 (95.36%) 
Hypernatremia (% of subjects) 0 (0.00%) 1 (2.32%) 1 (2.32%) 
Total (% of sample) 22 (51.17%) 21 (48.83%) 43 (100%) 
Conditions after being given treatment (t1) 
Hypo-Natremia (% of subjects) 0 (0.00%) 1 (2.32%) 1(2.32%) 
Normal (% of subjects) 22 (51.17%) 19 (44.19%) 41 (95.36%) 
Hyper-Natremia (% of subjects) 0 (0,00%) 1 (2.32%) 1 (2.32%) 
Total (% of sample) 22 (51.17%) 21 (48.83%) 43 (100%) 
 
Table 3: Frequency Distribution of Changes in Sodium Levels After Administration of Exacerbation Treatment with 
Aminofilin Intravenous or Nebulized Salbutamol 
Intervention Group Intravenous Aminophylline (n:22) Nebulized Salbutamol  
(n:21) 
Total 
Changes in the value t0 to t1 (ratio scale) 
Decreased (% of  subjects) 8 (18.61%) 6 (13,95%) 14 (32,56%) 
Consist of: 
-1 = ∑ 3 
-2 = ∑ 2 
-3 = ∑ 3 
Consist of: 
-1 = ∑ 2 
-2 = ∑ 4 
Fixed (% of subjects) 6 (13.95%) 9 (20,93%) 15 (34,88%) 
Increased (% of subjects) 8 (18.61%) 6 (13,95%) 14 (32,56%) 
Consist of: 
+1 = ∑ 6 
+2 = ∑ 2 
Consist of: 
+1 = ∑ 3 
+3 = ∑ 1 
+4 = ∑ 2 
Total (% of subjects) 22 (51.17%) 21 (48.83%) 43 (100%) 
Changes in the value t0 to t1 (ratio scale) 
Worsen (% of subjects) 0 (0.00%) 0 (0,00%) 0 
(0,00%) 
Fixed (% of subjects) 22 (51.17%) 21 (48,85%) 43 (100%) 
Consist of: 
N-to-N= ∑ 22 
Consist of: 
Ho-to-Ho= ∑ 1 
N-to-N= ∑ 19 
Hi-to-Hi= ∑ 1 
 
Recovered (% of subjects) 0 (0,00%) 0 (0,00%) 0 
(0,00%) 
Total (% of subjects) 22 (51.17%) 21 (48.83%) 43 (100%) 
Ho : hipo (under the normal level) 
N : normal 
Hi : hyper (above the normal level) 
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in patients with hypokalemia before getting the test drug  
therapy salbutamol group, it is made possible patients 
already using asthma medication for type of reliever on the 
way to the hospital emergency room to help alleviate the 
symptoms. Analysis of the data in this study used t-test, to 
determine differences in the incidence of changes in the 
electrolyte. Levels of potassium and sodium in the blood is 
the data that is included in the scale ratio of the need to use 
Kolmogorov-Smirnov test to test for two independent 
samples, to determine the normality of the data 
distribution. If the value of P> 0.05 means that the 
differences are not significant so H0 is accepted, while the 
value of P <0, 05 means that a significant difference so H1 
is received. Data interviews clinical conditions nominal 
data samples that can be analyzed descriptively. 
 
RESULT AND DISCUSSION 
Characteristics of the study subjects are shown in Table 1. 
In this study, the number of women were more than men, 
either in groups aminophylline intravenous or nebulized 
salbutamol. The age of the study subjects were in the 
productive age range, with average of 39.25 (intravenous 
aminophylline group) and 42.38 (nebulized salbutamol). A 
large part of their medical history was only had asthma 
without any other comorbidities (Table 1). At nebulized 
salbutamol’s population group, there were 4 patients who 
should be excluded because blood tests must be done in a 
laboratory outside the hospital and possibly due to factors 
in the journey that causes lysis of blood be on t0 or t1, so 
it can not be known sodium/ potassium level. 
Measurement of sodium/ potassium levels in the blood of 
patients in different laboratories can affect the results, 
because every instrument has different precision and 
accuracy, so the range of normal values can be different for 
different laboratories. Exacerbation of asthma patients 
used in the study was the rate of mild-moderate asthma 
who do not require another asthma treatment such as 
corticosteroids. Because the systemic corticosteroids 
group for asthma medications, ADR form 
methylprednisolon can cause hypokalemia, its use may 
cause sodium retention and increased secretion of 
potassium which can cause hypertension and 
hypokalemia22. Diabetic patients will be at risk of 
electrolyte disturbances, especially if they use drugs  
Table 4: Sodium Levels Test Changes Due to Aminofilin Intravenous Administration Compared to Nebulized 
Salbutamol Administration 
Intervention Group  Test Differences 
between t0 and t1 in 
the same group** 
(Paired T-Test) 
Test Differences 
between t0 in groups** 
(Independent T-Test) 
Test Differences 
between t1 in groups** 
(Independent T-Test) 
Intravenous 
Aminophylline 
(n:22) 
Sodium level 
before the 
treatment (t0) 
0,004 
(H1 accepted) 
0,736 (Not significant) 0,866 (Not significant) 
Sodium level 
after the 
treatment (t0) 
Nebulized 
Salbutamol (n:21) 
Sodium level 
before the 
treatment (t0) 
0,000 
(H1 accepted) 
Sodium level 
after the 
treatment (t0) 
* data is normal distribution if sig ≥ 0.05 
**data is homogen (not significant) if sig >0,05, H0 accepted and H1 rejected 
 
Table 5: Frequency Distribution of Potassium Levels Before and After Administration of Exacerbation Treatment with 
Aminofilin Intravenous or Nebulized Salbutamol 
Intervention Group Intravenous Aminophylline (n:22) Nebulized Salbutamol  
(n:21) 
Total 
Initial conditions before being given treatment (t0) 
Hypokalemia (% of subjects) 3 (6,98%) 3 (6,98%) 6 (13,95%) 
Normal  (% of subjects) 19 (44,19%) 18 (41,85%) 37 (86,05%) 
Hyperkalemia (% of subjects) 0 (0.00%) 0 (0,00%) 0 (0,00%) 
Total (% of sample) 22 (51.17%) 21 (48.83%) 43 (100%) 
Conditions after being given treatment (t1) 
Hypokalemia (% of subjects) 2 (4,65%) 5 (11,63%) 7 (16,28%) 
Normal  (% of subjects) 20 (46,51%) 16 (37,21%) 36 (83,72%) 
Hyperkalemia (% of subjects) 0 (0,00%) 0 (0,00%) 0 (0,00%) 
Total (% of subjects) 22 (51.17%) 21 (48.83%) 43 (100%) 
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exacerbate asthma who are at risk of the disorder. And in 
this study sample there was one person who had a history 
of diabetes mellitus type 2 (Table 1), which at the time of 
the study also experienced hypokalemia. Although the 
provision of nebulized salbutamol therapy only decreases 
by 2 points hypokalemia condition (condition of asthma 
patients after therapy is hypokalemia), but this still needs 
to be a particular concern. According Liamis et al. 
(2014),23 this electrolyte disturbances are particularly 
common in decompensated diabetics, especially in the 
context of diabetic ketoacidosis or nonketotic 
hyperglycemic hyperosmolar syndrome. These patients 
are markedly potassium-, magnesium- and phosphate-
depleted23.  Initial conditions in the intervention groups are 
relatively equal, that most have normal sodium level. Only 
in nebulized salbutamol group, there are 2 people who 
have levels outside the range, consist of 1 person 
experiencing hyponatremia (2.32%) and 1 person 
experiencing hypokalemia (2.32%). These conditions are 
also the same after intravenous administration of 
aminophylline therapy and intravenous salbutamol (Table 
2). Changes in sodium levels before given treatment (t0) 
and after given therapy (t1) can be seen in Table 3. The 
results showed that the intravenous aminophylline group 
showed decreasing in sodium levels as much as the 
improvement after therapy, ie by 18.61%, despite of all the 
changes they are still in the normal range. In the group of 
nebulized salbutamol, more number of samples did not 
change levels of sodium (20.93%), although there are some 
that decreased (13.95%) and increase (13.95%) of the 
levels. Just like aminophylline intravenous group, the 
nebulized salbutamol group also showed normal range of 
sodium levels (Table 3). Sodium levels data of the group 
aminophylline intravenous and nebulized salbutamol 
shows in table 4, both before treatment (t0) and after 
treatment (t1) indicates that all data distributed normally 
(p≥ 0.05). Both groups equally showed a significant 
difference between the sodium level before and after 
treatment (p (0.004) <0,05 and p (0.000) <0.05), which 
means there is a significant change in sodium levels with 
administration of intravenous aminophylline and 
salbutamol therapy nebulized. This study used a quasi-
experimental, and both groups interventional therapy 
derived from a different hospital (no random). To ascertain  
Table 6: Frequency Distribution of Changes in Potassium Levels After Administration of Exacerbation Treatment with 
Aminofilin Intravenous or Nebulized Salbutamol 
Intervention Group Intravenous Aminophylline (n:22) Nebulized Salbutamol  
(n:21) 
Total 
Changes in the value t0 to t1 (ratio scale) 
Decreased (% of  subjects) 8 (18.60%) 13 (30.23%) 21 (48.83%) 
Consist of: 
-0,2 = ∑ 5 
-0,3 = ∑ 2 
-0,4 = ∑ 1 
Consist of: 
-0,1 = ∑ 2 
-0,2 = ∑ 1 
-0,3 = ∑ 2 
-0,4 = ∑ 4 
-0,5 = ∑ 1 
-0,7 = ∑ 1 
-0,8 = ∑ 1 
-1,0 = ∑ 1 
Fixed (% of subjects) 9 (20.93%) 5 (11.63%) 14 (32.56%) 
Increased (% of subjects) 5 (11.63%) 3 (6.98%) 8 (18.64%) 
Consist of: 
+0,1 = ∑ 3 
+0,3 = ∑ 1 
+0,4 = ∑ 1 
Consist of: 
+0,1 = ∑ 1 
+0,2 = ∑ 1 
+0,8 = ∑ 1 
Total (% of subjects) 22 (51.17%) 21 (48.83%) 43 (100%) 
Changes in the value t0 to t1 (ratio scale) 
Worsen (% of subjects) 0 (0.00%) 3 (6.98%) 3 
(6.98%)  Consist of: 
N-to-Ho= ∑ 3 
Fixed (% of subjects) 21 (48.84%) 17 (39.53%) 38 
(88.37%) Consist of: 
Ho-to-Ho= ∑ 1 
N-to-N= ∑ 20 
Consist of: 
Ho-to-Ho= ∑ 2 
N-to-N= ∑ 15 
Recovered (% of subjects) 1 (2.33%) 1 (2.33%) 2 
(4,65%) Consist of: 
Ho-to-N= ∑ 1 
Consist of: 
Ho-to-Ho= ∑ 1 
Total (% of subjects) 22 (51.17%) 21 (48.83%) 43 (100%) 
Ho : hipo (under the normal level) 
N : normal 
Hi : hyper (above the normal level) 
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whether the two groups have the same sodium content 
databases then the data was analyzed using t-test between 
groups (t0), and the result showed no significant difference 
in sodium content between the two groups in the time 
before t0 therapy (p>0.736), so that it can be ascertained 
that potassium levels in both groups was the same. In 
addition, the results of sodium levels after administration 
of the therapy also showed no significant difference 
between the two groups (p>0.866) (Table 4). Initial 
conditions of the intervention groups are relatively equal, 
that most have normal potassium levels. At nebulized 
aminophylline group, most of the samples have normal 
potassium levels (44.19%), although 6.96% of them had 
hypokalemia. Similarly with nebulized salbutamol group, 
most of the samples had normal potassium levels 
(41.85%), with 6.98% of them had hypokalemia. None of 
the subjectsshowed specific symptoms of hypokalemia 
although the potassium level is below the normal range. 
Similar conditions also occured during exacerbations of 
asthma after therapy in each group. In the group of 
intravenous aminophylline, the number of patients with 
normal potassium levels were increased to 46.51%. In the 
other side, the salbutamol group showed an increasing 
number of subjects that experienced hypokalemia to be 
11.63% (Table 5). Changes in potassium levels before 
given treatment (t0) and after given therapy (t1) can be 
seen in Table 6. The results showed that most of the subject 
who received intravenous aminophylline therapy had 
higher levels of potassium which is fixed (20.93%). Based 
on the value of the normal range, all the samples in the 
group were in the normal range even there is one patient 
who experienced improvement from hypokalemia 
becomes normal. There is a theory that theophylline 
increases production of urine and enhances excretion of 
water and electrolytes24. The total number of patients with 
chronic asthma and low serum sodium levels was too small 
to draw a clear conclusion about its prevalence and clinical 
significance, further studies with a larger number of 
subjects are needed to evaluate the significance of this 
finding (Table 6). Contrast with nebulized salbutamol 
group, which is largely decreased the potassium levels as 
much as 30.23%, and only 11.63% were fixed. Based on 
the value of the normal range, this group also experienced 
improvements majority (39.53%), even one patient 
experienced improvement from hypokalemia becomes 
normal. However, the concern is that there are 3 subjects 
(6.98%) experienced worsening of normal potassium 
levels (t0) becomes hypokalemia (t1) even though they do 
not show specific symptoms of hypokalemia and not 
require treatment (Table 6). Asthma patients who used the 
drug may cause hypokalemia. In this case, β2 agonist that 
has been widely transparently reported salbutamol can lead 
to hypokalaemia. The β2 adrenergic receptor stimulation 
by sympathomimetic drugs such as bronchodilators can 
reduce levels of serum potassium. Therapeutic doses of 
nebulized salbutamol can lower potassium levels of 0,2 
mmol/L to 0,4 mmol/L25. The incidence of hypokalemia in 
the aminophylline treatment group was less than 
salbutamol. Hypokalemia can occur due to the transfer of 
potassium from the intravascular to normal intraseluler. 
Distribution of potassium between cells and the 
extracellular fluid is maintained by Na-K-ATPase 
pumping reside in cell membranes. In certain 
circumstances may an increasing in the rate of potassium 
into the cell transients. Hypokalemia is usually associated 
with increasing morbidity and mortality, in particular 
because of arrhythmia or sudden cardiac death. 
Hypokalemia is a result of the overall deficit or shift 
potassium serum potassium into the intracellular 
compartments in the body26. Besides, there is also a theory 
that hypokalemia may occur due to active inhibition of 
potassium secretion in the cortical collecting tubule, 
possibly the caused by the stimulation of membrane-
dependent sodium potassium adenosine triphosphatase 
that results in hyper polarization of the cellular membrane 
potential27. In this study clinical interview conducted 
directly to the subject of research and also assisted by his 
family. Hypokalemia clinical symptoms such as 
Table 7: Potassium Levels Test Changes Due to Differences in Aminofilin Intravenous Administration Compared with 
Nebulized Salbutamol 
  Test Differences 
between t0 and t1 in 
the same group** 
(Paired T-Test) 
Test Differences 
between t0 in groups** 
(Independent T-Test) 
Test Differences 
between t1 in groups** 
(Independent T-Test) 
Intravenous 
Aminophylline 
(n:22) 
Kalium level 
before the 
treatment (t0) 
0.000 
(H1 accepted) 
0.569  
(Not significant) 
0.470  
(Not significant) 
Kalium level 
after the 
treatment (t0) 
Nebulized 
Salbutamol (n:21) 
Kalium level 
before the 
treatment (t0) 
0.001 
(H1 accepted) 
Kalium level 
after the 
treatment (t0) 
* data is normal distribution if sig ≥ 0.05 
**data is homogen (not significant) if sig >0.05, H0 accepted and H1 rejected 
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arrhythmias, can not be known because it requires an 
electrocardiogram (ECG) to determine the cardiac patient 
records. The ECG examination was not done because the 
patient objected to undress like commonly done for heart 
disease patients. Hypokalemia contribute to an increased 
risk of arrhythmia, it occurs most frequently in acute 
myocardial infarction (MI) at pulse rate greater than 
100x/min. Hypokalemia can cause patients to experience 
muscle fatigue or cramps and serious cardiac aritmia and 
sudden death. Treatment of hypokalemia, In general, each 
1mmol/L potassium fall below 3.5 mmol/L in accordance 
with the total body deficit of 100-400 mEq. When possible, 
potassium supplements should be given orally. Of salt 
available, potassium chloride is most commonly used as 
the most effective for the common cause of potassium 
depletion. The use of IV should be restricted to patients 
who have severe hypokalemia, signs and symptoms of 
hypokalemia, or inability to tolerate oral therapy. 
Potassium must be administered in salt, because dextrose 
so as to stimulate the secretion of insulin and worsen 
intracellular potassium shifts. Generally, 10 to 20 mEq of 
potassium diluted in 100 mL of 0,9% saline and 
administered through a peripheral vein over 1 hour. If the 
infusion rate exceeds 10 mEq/hr, ECG should be 
monitored26. Data potassium levels of the group 
aminophylline intravenous and nebulized salbutamol 
shows in table 7, both before treatment (t0) and after 
treatment (t1) indicates that all data normal distribution 
(p≥0.05). Both groups equally showed a significant 
difference between the potassium levels before and after 
treatment (p(0.000)<0.05 and p(0.001)<0.05), which 
means that there is a significant change in potassium levels 
with administration of intravenous aminophylline and 
salbutamol therapy nebulized. The two groups have the 
same potassium levels databases then analized with t-test 
between groups (t0), and the result showed no significant 
difference in potassium levels between the two groups 
before t0 therapy (p>0.569), so that it can be ascertained 
condition potassium levels in both groups was the same. 
The results of potassium levels after administration of the 
therapy also showed no significant difference between the 
two groups (p> 0.470) (Table 7). Both β2-agonist and 
aminophylline group was known can cause hypokalemia 
as adverse drug reaction event28,29. Nebulized salbutamol 
administration for the emergency treatment of acute 
exacerbations of asthma associated with a statistically 
significant decrease in serum potassium levels decreased 
significantly29. Salbutamol cause hypokalemia which 
correlates with a decrease in respiratory rate (RR), and an 
increase in venous oxygen tension (pO2) and peak 
expiratory flow (PEF). These findings suggest that the 
same mechanism is involved in eliciting hypokalemia and 
bronchodilation19. Hypokalemia in patients with asthma 
can be life-threatening plasma potassium concentration of 
1.7 mEq/L and can be exacerbated by a combination 
treatment with other drugs such as diuretics, 
corticosteroids and theophylline which resulted in loss of 
potassium28. Paralysis can suddenly occur in both lower 
limbs due to improper treatment. Administration of inhaled 
β2-agonist continuously can cause paralysis due to 
hypokalaemic though is the drug of choice to overcome 
asthma exacerbations30.  
 
CONCLUSION 
There is no significant difference in levels of sodium and 
potassium in the treatment of asthma exacerbations by 
intravenous aminophylline compared with nebulized 
salbutamol. And the majority of subjects showed normal 
values in its levels of potassium and sodium, both of 
intravenous aminophylline or nebulized salbutamol. 
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